The Relative Strength (RS) Rating for Ligand Pharmaceuticals entered a new percentile Thursday, with a rise from 80 to 85.
This exclusive rating from Investor's Business Daily identifies price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buying range in heavy volume.
Ligand Pharmaceuticals posted -8% EPS growth in the latest quarterly report. Sales gains came in at 52%. The company is expected to report its latest numbers on or around Apr. 30.
Ligand Pharmaceuticals holds the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
